Brown Brothers Harriman & Co’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-26
| Closed | -$1.83K | – | 1477 |
|
|
2024
Q3 | $1.83K | Buy |
+26
| New | +$2.17K | ﹤0.01% | 1314 |
|
|
2024
Q2 | – | Sell |
-266
| Closed | -$23.2K | – | 1163 |
|
|
2024
Q1 | $23.2K | Hold |
266
| – | – | ﹤0.01% | 871 |
|
|
2023
Q4 | $25.6K | Sell |
266
-600
| -69% | -$53.1K | ﹤0.01% | 820 |
|
|
2023
Q3 | $76.6K | Sell |
866
-134
| -13% | -$11.9K | ﹤0.01% | 647 |
|
|
2023
Q2 | $86.7K | Hold |
1,000
| – | – | ﹤0.01% | 622 |
|
|
2023
Q1 | $97.2K | Hold |
1,000
| – | – | ﹤0.01% | 617 |
|
|
2022
Q4 | $103K | Sell |
1,000
-360
| -26% | -$33.8K | ﹤0.01% | 591 |
|
|
2022
Q3 | $115K | Buy |
1,360
+143
| +12% | +$12.7K | ﹤0.01% | 564 |
|
|
2022
Q2 | $101K | Buy |
1,217
+217
| +22% | +$17.3K | ﹤0.01% | 576 |
|
|
2022
Q1 | $77K | Hold |
1,000
| – | – | ﹤0.01% | 676 |
|
|
2021
Q4 | $88 | Hold |
1,000
| – | – | ﹤0.01% | 609 |
|
|
2021
Q3 | $77 | Hold |
1,000
| – | – | ﹤0.01% | 602 |
|
|
2021
Q2 | $83 | Hold |
1,000
| – | – | ﹤0.01% | 586 |
|
|
2021
Q1 | $76 | Sell |
1,000
-105
| -10% | -$8.58K | ﹤0.01% | 567 |
|
|
2020
Q4 | $97K | Buy |
+1,105
| New | +$87.6K | ﹤0.01% | 557 |
|
|
2019
Q3 | – | Sell |
-10
| Closed | -$1K | – | 1196 |
|
|
2019
Q2 | $1K | Sell |
10
-30
| -75% | -$2.57K | ﹤0.01% | 991 |
|
|
2019
Q1 | $4K | Buy |
+40
| New | +$3.71K | ﹤0.01% | 912 |
|
|
2018
Q1 | – | Sell |
-40
| Closed | -$4K | – | 838 |
|
|
2017
Q4 | $4K | Buy |
+40
| New | +$3.48K | ﹤0.01% | 874 |
|
|
2017
Q3 | – | Sell |
-12
| Closed | -$1K | – | 739 |
|
|
2017
Q2 | $1K | Hold |
12
| – | – | ﹤0.01% | 736 |
|
|
2017
Q1 | $1K | Sell |
12
-341
| -97% | -$30.3K | ﹤0.01% | 772 |
|
|
2016
Q4 | $29K | Buy |
+353
| New | +$30.4K | ﹤0.01% | 566 |
|
|
2016
Q1 | – | Sell |
-230
| Closed | -$24K | – | 680 |
|
|
2015
Q4 | $24K | Hold |
230
| – | – | ﹤0.01% | 543 |
|
|
2015
Q3 | $24K | Hold |
230
| – | – | ﹤0.01% | 587 |
|
|
2015
Q2 | $31K | Hold |
230
| – | – | ﹤0.01% | 551 |
|
|
2015
Q1 | $29K | Hold |
230
| – | – | ﹤0.01% | 566 |
|
|
2014
Q4 | $21K | Hold |
230
| – | – | ﹤0.01% | 634 |
|
|
2014
Q3 | $17K | Hold |
230
| – | – | ﹤0.01% | 633 |
|
|
2014
Q2 | $14K | Hold |
230
| – | – | ﹤0.01% | 637 |
|
|
2014
Q1 | $16K | Hold |
230
| – | – | ﹤0.01% | 627 |
|
|
2013
Q4 | $16K | Buy |
+230
| New | +$15.6K | ﹤0.01% | 560 |
|
Other funds holding BMRN
EIM
Brown Brothers Harriman & Co's BMRN Position: Q4 2024 in Review
Brown Brothers Harriman & Co sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2024, closing a stake of 26 shares — an estimated $1.83K sold.
Brown Brothers Harriman & Co first reported a position in BMRN in Q4 2013 and held it in 30 quarters. The position peaked at $115K in Q3 2022. 543 funds tracked by Wall St. Rank hold BMRN as of Q4 2024.
- Brown Brothers Harriman & Co reported no remaining BioMarin Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
- Brown Brothers Harriman & Co sold 26 BioMarin Pharmaceuticals shares in Q4 2024, an estimated $1.83K.
- Brown Brothers Harriman & Co first reported a position in BioMarin Pharmaceuticals in Q4 2013 and held it in 30 quarters.
- Brown Brothers Harriman & Co's BioMarin Pharmaceuticals position peaked at $115K in Q3 2022.
- 543 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2024.
Based on Brown Brothers Harriman & Co's 13F filing for Q4 2024, filed 12 Feb 2025.